Amyloidosis — Trials · CancerIndex

Clinical trials

Registered studies

47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 33%
Top sponsor: Alexion Pharmaceuticals, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05145816	Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis	recruiting	Phase 1 / Phase 2	37	University of Texas Southwestern Medical CenterOTHER	1	Aug 19, 2026	clinicaltrials
NCT07081646	A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.(ALACRITY)	recruiting	Phase 1 / Phase 2	91	Alexion Pharmaceuticals, Inc.INDUSTRY	3	Jul 2, 2026